BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS
Jazmin Acosta,Yonas E. Geda,Gorazd B. Stokin,Adam S. Fleisher,Cole Reschke,Robert J. Bauer,Pradeep Thiyyagura,Bai Lu,Richard J. Caselli,Michael Weiner,Eric M. Reiman,Kewei Chen
DOI: https://doi.org/10.1016/j.jalz.2014.05.816
2014-01-01
Abstract:Among cognitively unimpaired persons with florbetapir positron emission tomography (PET) evidence of significant fibrillar amyloid-β (Aβ) burden from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, carriers of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism were distinguished from non-carriers by greater 36-month rates of memory, language, executive function, and hippocampal volume declines. Here, Alzheimer's Disease Neuroimaging Initiative (ADNI) data were used to investigate whether baseline measurements and 24-month changes in fibrillar Aβ deposition and neuropsychologist test scores were differentially affected by BDNF-Met carrier status in cognitively unimpaired individuals. 14 cognitively unimpaired BDNF-Met carriers, aged 76-94 years, and 20 non-carriers, aged 70-89 years, had baseline and 24-month follow-up clinical ratings, neuropsychological tests, florbetapir PET, and magnetic resonance imaging (MRI) scans. Standard uptake value ratios (SUVRs) with cerebellum reference region were used to quantify PET fibrillar Aβ burden. T-tests were used to compare baseline measurements and 24-month changes in mean cortical florbetapir SUVRs, hippocampal volumes, and performance on 10 neuropsychological tests. Except for age (carriers=82.52±5.78, non-carrie r s= 78.63±4.49, p=0.03), at baseline, BDNF-Met carriers and non-carriers did not differ in their gender ratios, years of education, proportions of apolipoprotein (APOE) ε4 carriers, Mini-Mental State Examination scores, florbetapir SUVRs, or hippocampal volumes. Interestingly, for baseline Auditory Verbal Learning Test (AVLT) scores, BDNF-Met carriers exhibited greater memory retention relative to non-carriers with (p=0.05) or without (p=0.03) accounting for age. BDNF-Met carriers were, however, distinguished from non-carriers by greater 24-month mean cortical florbetapir SUVR increases with ages accounted for (p=0.003) or not (p=0.02). Similarly, the BDNF-Met carriers had greater 24-month decline on AVLT long-term recall scores again with (p=0.009) or without (p=0.003) co-varying out age (but uncorrected for multiple neuropsychological tests). The groups, however, did not differ significantly in their 24-month changes of hippocampal volume or other neuropsychological test performance scores (p>0.05). This study raises the possibility that BDNF Val66Met allele is associated with accelerated rates of memory decline and greater amyloid deposition in cognitively normal adults. Additional studies are needed to confirm these preliminary findings and clarify the manner in which BDNF influences pathogenesis of Alzheimer's disease.